Marc André

7.1k total citations
121 papers, 1.7k citations indexed

About

Marc André is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marc André has authored 121 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pathology and Forensic Medicine, 41 papers in Oncology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marc André's work include Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Lung Cancer Treatments and Mutations (23 papers). Marc André is often cited by papers focused on Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Lung Cancer Treatments and Mutations (23 papers). Marc André collaborates with scholars based in Belgium, France and United States. Marc André's co-authors include André Bosly, Augustin Ferrant, Pauline Brice, Gregor Verhoef, Pierre W. Wijermans, Regina Kunzmann, Michael Lübbert, Christophe Ravoet, Olivier Casasnovas and Marine Diviné and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Marc André

110 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc André Belgium	19	1.1k	731	394	392	329	121	1.7k
Martina Chiarucci Italy	6	1.3k 1.1×	904 1.2×	399 1.0×	221 0.6×	323 1.0×	10	1.7k
Amalia De Renzo Italy	27	997 0.9×	815 1.1×	300 0.8×	203 0.5×	499 1.5×	74	2.1k
Cherie H. Dunphy United States	24	817 0.7×	683 0.9×	215 0.5×	305 0.8×	519 1.6×	127	2.0k
Daniel Ré Germany	22	1.0k 0.9×	829 1.1×	211 0.5×	329 0.8×	322 1.0×	62	1.9k
Emmanuel Bachy France	26	1.2k 1.1×	1.3k 1.8×	204 0.5×	172 0.4×	450 1.4×	185	2.3k
Alessandro Broccoli Italy	22	1.2k 1.1×	631 0.9×	375 1.0×	262 0.7×	326 1.0×	116	1.6k
Nicole Grant United States	14	1.2k 1.1×	934 1.3×	563 1.4×	152 0.4×	605 1.8×	37	1.8k
DC Linch United Kingdom	19	949 0.9×	720 1.0×	256 0.6×	174 0.4×	397 1.2×	37	1.5k
Dai Chihara United States	25	1.2k 1.1×	932 1.3×	352 0.9×	171 0.4×	662 2.0×	128	2.1k
Rémy Gressin France	26	1.7k 1.6×	1.2k 1.6×	370 0.9×	261 0.7×	880 2.7×	109	2.5k

Countries citing papers authored by Marc André

Since Specialization

Citations

This map shows the geographic impact of Marc André's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc André with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc André more than expected).

Fields of papers citing papers by Marc André

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc André. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc André. The network helps show where Marc André may publish in the future.

Co-authorship network of co-authors of Marc André

This figure shows the co-authorship network connecting the top 25 collaborators of Marc André. A scholar is included among the top collaborators of Marc André based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc André. Marc André is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gouill, Steven Le, Virginie De Wilde, Toby A. Eyre, et al.. (2024). Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial. Blood. 144(Supplement 1). 745–745. 1 indexed citations

Brody, Joshua, David Belada, Régis Costello, et al.. (2024). Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.. Journal of Clinical Oncology. 42(16_suppl). 7037–7037. 3 indexed citations

Delfau, Marie Hélène, Emmanuel Bachy, Franck Morschhauser, et al.. (2023). Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study. Hematological Oncology. 41(S2). 338–339. 1 indexed citations

Belada, David, Kateřina Kopečková, Juan Bergua, et al.. (2023). Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 142(16). 1348–1358. 12 indexed citations

Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2023). Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Blood. 142(Supplement 2). LBA–2. 13 indexed citations

Kiciński, Michal, Marleen A. E. van der Kaaij, Francesco Giusti, et al.. (2022). Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials. Journal of Cancer Survivorship. 18(3). 727–738. 4 indexed citations

Vachon, Hugo, Madeline Pe, Corneel Coens, et al.. (2021). Reference values for the EORTC QLQ‐C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. European Journal Of Haematology. 106(5). 697–707. 3 indexed citations

Włodarska, Iwona, Olivier Gheysens, Luc Dehaspe, et al.. (2021). The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. Blood Advances. 5(7). 1991–2002. 18 indexed citations

Gondran‐Tellier, Bastien, Richard J. McManus, S. Gaillet, et al.. (2020). Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary?. Abdominal Radiology. 45(12). 4160–4165. 5 indexed citations

10.

Neste, Éric Van Den, Marc André, Thomas Gastinne, et al.. (2018). A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica. 103(5). 840–848. 42 indexed citations

11.

Bonnet, Christophe, Ann Janssens, Thomas Tousseyn, et al.. (2015). BHS Guidelines for the treatment of Burkitt’s lymphoma. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 6(2). 61–69. 5 indexed citations

12.

Mounier, Nicolas, Pauline Brice, Serge Bologna, et al.. (2014). ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of Oncology. 25(8). 1622–1628. 66 indexed citations

13.

Verhoef, G., Wilfried Schroyens, Dominique Bron, et al.. (2013). Guidelines for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and relapsed DLBCL. Open Repository and Bibliography (University of Liège). 4(2). 51–57. 2 indexed citations

14.

Neste, Eric Van Den, Olivier Casasnovas, Marc André, et al.. (2013). Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 98(8). 1185–1195. 35 indexed citations

15.

Mounier, Nicolas, Renaud Lhommel, S Costantini, et al.. (2013). Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leukemia & lymphoma. 55(4). 773–780. 59 indexed citations

16.

Tilly, Hervé, Umberto Vitolo, Jan Walewski, et al.. (2012). Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23. vii78–vii82. 122 indexed citations

17.

Morschhauser, Franck, Pauline Brice, Christophe Fermé, et al.. (2008). Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group. Journal of Clinical Oncology. 26(36). 5980–5987. 90 indexed citations

18.

André, Marc, Nicolas Mounier, Xavier Leleu, et al.. (2001). Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients.. Blood. 98(11). 4 indexed citations

19.

André, Marc, et al.. (1996). Retroviral-mediated gene transfer of murine IL-12 into tumor cells and fibroblasts as a strategy to increase the host anti-tumor immune system. Cancer Gene Therapy. 3(6). 24. 1 indexed citations

20.

André, Marc. (1958). Acariens Thrombidions (adultes) de l'Angola. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact